Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Torgerson, J. S
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Preventing diabetes in the obese: the XENDOS study and its context

Jarl S Torgerson

Department of Body Composition and Metabolism, Vita Stråket 15, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden, jarl.torgerson{at}medfak.gu.se

This article reviews the evidence, from both observational epidemiology and randomised clinical trials, that lifestyle modification as well as anti-diabetic drugs can reduce or delay the development of diabetes in overweight and obese patients with IGT. Particular consideration is given to the recently published XENDOS study which showed that the combination of orlistat and lifestyle changes over four years is safe and well tolerated, results in a weight loss of about six kg and reduces the risk of developing diabetes by 45% in obese IGT patients. Thus, addition of orlistat to lifestyle intervention has a greater diabetes-preventing effect than lifestyle modification alone.

Key Words: diabetes • obesity • prevention • lifestyle • drug treatment.

References

  • World Health Organization. Obesity: Preventing and managing the global epidemic. WHO Technical Report Series 894. World Health Organization, Geneva, 2000.
  • Diabetes Atlas, second edition. IDF 2003. www.idf.org/e-atlas
  • Powers AC Diabetes mellitus. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL eds. Harrison's principles of internal medicine 15th edition. New York: McGraw-Hill, 2001:2109-37.
  • Eriksson J., Lindström J., Valle T. et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Diabetologia 1999;42:793-801.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Zimmet P., Alberti Kgmm, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Unwin N., Shaw J., Zimmet P. et al. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002;19:708-23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wolf AM, Colditz AG Current estimates of the economic cost of obesity in the United States. Obes Res 1998;6:97-106.[Web of Science][Medline] [Order article via Infotrieve]
  • Williamson DF, Thompson TJ, Thun M. et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000;23:1499-504.[Abstract]
  • Pinkney JH, Sjöström CD, Gale EAM. Should surgeons treat diabetes in severely obese people? Lancet 2001;357:1357-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • MacDonald KG, Long SD, Swanson MS et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997;1:243-20.
  • Poires WJ, Swanson MS, MacDonald KG et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset
  • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Joslin EP The prevention of diabetes mellitus. JAMA 1921;76:79-84.[Abstract/Free Full Text]
  • World Health Organization. Prevention of diabetes mellitus. WHO Technical Report Series 844. World Health Organization, Geneva, 1994.
  • Pinkney J. Prevention and cure of type 2 diabetes. BMJ 2002;325:232-3.[Free Full Text]
  • Eriksson KF, Lindgärde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia 1991;34:891-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care 1997;20:537-44.[Abstract]
  • Hu FB, Manson JE, Stampfer MJ et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;345:790-7.[Abstract/Free Full Text]
  • Toumilehto J., Lindström J., Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.[Abstract/Free Full Text]
  • Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.[Abstract/Free Full Text]
  • Heymsfield SB, Segal KR, Hauptman J. et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000;160:1321-6.[Abstract/Free Full Text]
  • Torgerson JS, Hauptman J., Boldrin MN et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.[Abstract/Free Full Text]
  • Chiasson Jl, Josse RG, Gomis R. et al. Acarbose for the prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359:2072-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic b-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-803.[Abstract/Free Full Text]
  • Sjöström CD, Peltonen M., Wedel H. et al. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000;36:20-5.[Abstract/Free Full Text]
  • Sjöström L. Surgical intervention as a strategy for treatment of obesity. Endocrine 2000;13:213-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Long SD, O'Brien K., MacDonald KG et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. Diabetes Care 1994;17:372-5.[Abstract]
  • Diabetes Prevention Program Research Group. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999;22:623-34.[Abstract]
  • Chiasson JL, Gomis R., Hanefeld M. et al. The STOP-NIDDM trial. An interventional study on the efficacy of an {alpha}-glucosidase inhibitor to prevent type 2 I diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Diabetes Care 1998;21: 1720-5.[Abstract]
  • Chiasson JL, Josse RG, Gomis R. et al. Acarbose treatment and risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM trial. JAMA 2003;290:486-94.[Abstract/Free Full Text]
  • Azen SP, Berkowitz K., Kjos S. et al. TRIPOD: a randomised placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998;19:217-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sparre Hermann L., Wiernsperger N. Impaired glucose tolerance and metformin: clinical and mechanistic aspects. Br J Diabetes Vasc Dis 2002;2: 177-83.[Abstract/Free Full Text]
  • Parker JC Troglitazone: the discovery and development of a novel therapy for the treatment of type 2 diabetes mellitus. Adv Drug Deliv Rev 2002;54:1173-97.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992;55:309-13.
  • Torgerson JS, Arlinger K., Käppi M. et al. Principles for enhanced recruitment of subjects in a large clinical trial: The XENDOS study experience. Control Clin Trials 2001;22:515-25.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Richard JL, Sultan A., Daures JP et al. Diagnosis of diabetes mellitus and intermediate glucose abnormalities in obese patients based on ADA (1997) and WHO (1985) criteria. Diabet Med 2002;19:292-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Borch-Johnsen K. IGT and IFG. Time for revision? Diabet Med 2002;19: 707.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wylie G., Hungin APS, Neely J. Impaired glucose tolerance: qualitative and quantitative study of general practitioners' knowledge and perceptions. BMJ 2002;324:1190-2.[Abstract/Free Full Text]
  • Miles JM, Leiter L., Hollander P. et al. Effects of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002;25:1123-8.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 1, 22-27 (2004)
DOI: 10.1177/14746514040040010401
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Torgerson, J. S
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?